Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Our Commitment

Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d

Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia

Simon Manyara

Simon Manhara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.

Transboundary and Emerging Diseases | Boehringer Ingelheim US

Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.

Medicine & Regulatory Affairs

Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease

Data shows JARDIANCE reduced the risk for new-onset or worsening kidney disease in adults with T2D with established CV disease. View ISI, PI & Med Guide.

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions

Welcome to Innovation @ Boehringer Ingelheim

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US

Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.

Why today’s depression trials demand smart new approaches

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Human Health Innovation

Pipeline

Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Cardiologists at the Heart of Cardio-Renal-Metabolic Care

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

More Potential

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Corporate Profile

Our Mission

Our Story

The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease

Mohamed Eid shares his perspective on the role endocrinologists and primary care professionals play in diagnosing chronic kidney disease.

Partnering Days

What our partners say

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

About Us

Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Our Commitment

Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia

Simon Manyara

Transboundary and Emerging Diseases | Boehringer Ingelheim US

Medicine & Regulatory Affairs

Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

Welcome to Innovation @ Boehringer Ingelheim

New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF

Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US

Why today’s depression trials demand smart new approaches

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Human Health Innovation

Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

More Potential

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Corporate Profile

Our Mission

The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease

Partnering Days

What our partners say

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

About Us